A real-world study reveals the need for increased homologous repair deficiency and BRCA1/2 testing in patients with ovarian ...

Elementary schools throughout the East Meadow School District celebrated reading during PARP Week.

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

This enzyme is key to DNA repair in cells, so blocking it leads to cell death. Though PARP inhibitors are already approved to treat certain cancers, they come with toxicity risks thought to be ...

The new drug development corporation Daimbio announced on the 25th that it has completed a series A funding round worth 12 ...

In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake ...

“With our recently implemented trial protocol, we expect to initiate patient enrollment soon and further investigate stenoparib’s dual mechanisms of action—both as a PARP inhibitor and as a ...

Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...

Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.